These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 9370549)
1. Contrast enhancement issues in the MR evaluation of the central nervous system. Colosimo C; Manfredi R; Tartaglione T Eur Radiol; 1997; 7 Suppl 5():231-7. PubMed ID: 9370549 [TBL] [Abstract][Full Text] [Related]
2. Central nervous system: review of clinical use of contrast media. Runge VM; Muroff LR; Jinkins JR Top Magn Reson Imaging; 2001 Aug; 12(4):231-63. PubMed ID: 11687713 [TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging of the central nervous system in children with a new nonionic gadolinium contrast agent--gadoteridol injection (ProHance). Byrd SE; Darling CF; Wilczynski MA J Natl Med Assoc; 1993 May; 85(5):361-6. PubMed ID: 8496990 [TBL] [Abstract][Full Text] [Related]
4. Safety and diagnostic efficacy of gadoteridol for magnetic resonance imaging of the brain and spine in children 2 years of age and younger. Shah CC; Spampinato MV; Parmar HA; Raslan OA; Tomà P; Lin DDM; Vymazal J; Colosimo C; Enterline DS Pediatr Radiol; 2021 Sep; 51(10):1895-1906. PubMed ID: 33950270 [TBL] [Abstract][Full Text] [Related]
5. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Yuh WT; Fisher DJ; Engelken JD; Greene GM; Sato Y; Ryals TJ; Crain MR; Ehrhardt JC Radiology; 1991 Aug; 180(2):485-91. PubMed ID: 2068317 [TBL] [Abstract][Full Text] [Related]
6. Basic principles of MR contrast. Nelson KL; Runge VM Top Magn Reson Imaging; 1995; 7(3):124-36. PubMed ID: 7654392 [TBL] [Abstract][Full Text] [Related]
7. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Akeson P; Jonsson E; Haugen I; Holtås S Neuroradiology; 1995 Apr; 37(3):229-33. PubMed ID: 7603600 [TBL] [Abstract][Full Text] [Related]
8. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients. Kuhn MJ; Hammer GM; Swenson LC; Youssef HT; Gleason TJ Comput Med Imaging Graph; 1994; 18(5):391-9. PubMed ID: 7954317 [TBL] [Abstract][Full Text] [Related]
9. Central nervous system tumor, infection, and infarction: detection with gadolinium-enhanced magnetization transfer MR imaging. Mehta RC; Pike GB; Haros SP; Enzmann DR Radiology; 1995 Apr; 195(1):41-6. PubMed ID: 7892492 [TBL] [Abstract][Full Text] [Related]
10. [Detectability of metastatic brain tumors using gadoteridol-enhanced MRI: usefulness of standard-dose T1-weighted spin-echo image with magnetization transfer and enhanced FLAIR]. Annoura K; Utsunomiya H; Arai S; Okazaki M Nihon Igaku Hoshasen Gakkai Zasshi; 2000 Mar; 60(3):77-82. PubMed ID: 10741113 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Oudkerk M; Sijens PE; Van Beek EJ; Kuijpers TJ Invest Radiol; 1995 Feb; 30(2):75-8. PubMed ID: 7782190 [TBL] [Abstract][Full Text] [Related]
13. Rationale and clinical indications for contrast agents in MR imaging of the brain and spine. Atlas SW J Comput Assist Tomogr; 1993; 17 Suppl 1():S1-7. PubMed ID: 8486825 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the safety of standard and triple dose gadodiamide injection in MR imaging of the central nervous system. A double-blind study. Svaland MG; Christensen T; Lundorf E Acta Radiol; 1994 Jul; 35(4):396-9. PubMed ID: 8011392 [TBL] [Abstract][Full Text] [Related]
15. Review of the use of high-dose gadoteridol in the magnetic resonance evaluation of central nervous system tumors. Yuh WT; Fisher DJ; Mayr-Yuh NA; Tali ET; Nguyen HD; Gao F; Ehrhardt JC Invest Radiol; 1992 Aug; 27 Suppl 1():S39-44. PubMed ID: 1506152 [No Abstract] [Full Text] [Related]
16. [Brain magnetic resonance with magnetization transfer in multiple sclerosis. Lesion hyperintensity before and after intravenous gadolinium administration]. Renzetti P; Parodi RC; Losacco C; Rosso E; Arcuri T; Sardanelli F Radiol Med; 1999 Sep; 98(3):138-43. PubMed ID: 10575442 [TBL] [Abstract][Full Text] [Related]
17. Consecutive acquisition of time-resolved contrast-enhanced MR angiography and perfusion MR imaging with added dose of gadolinium-based contrast agent aids diagnosis of suspected brain metastasis. Tsuchiya K; Aoki S; Shimoji K; Mori H; Kunimatsu A Magn Reson Med Sci; 2013; 12(2):87-93. PubMed ID: 23666159 [TBL] [Abstract][Full Text] [Related]
18. The role of gadolinium-diethylenetriaminepentaacetic acid in the evaluation of the central nervous system. Runge VM; Gelblum DY Magn Reson Q; 1990 Apr; 6(2):85-107. PubMed ID: 2202425 [No Abstract] [Full Text] [Related]
19. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T. Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514 [TBL] [Abstract][Full Text] [Related]